Ask, Tell

When I was designing these marks a year ago, I wanted to acknowledge GLBTQI military persons serving under the unjust policy of Don\u27t Ask, Don\u27t Tell. To accomplish this, one of the counterforms in each of the military branch logos is flipped upside down creating the GLBTQI symbol of an inverted triangle. On September 20th, 2011, the Don\u27t Ask, Don\u27t Tell policy was repealed. Before the repeal, the simple act of wearing a t-shirt with one of these logos on it would have been an act of defiance and resistance. Today that same mark serves as a celebration of this significant step toward social justice being realized for GLBTQI citizens

Instant Racism

Ubiquitous messages are, by definition, everywhere and therefore familiar to us. Due to the nature of attention, the familiar often gets past critical filters because it feels so comfortable. After all, there is nothing different or alarming about the familiar. I am interested in the powerful ability of graphic design to reframe the ubiquitous because once we see something differently, we never see it the same again. I was inspired to create this work after reading Clinging to Mammy: The Faithful Slave in Twentieth-Century America in which author Micki McElya critically examines the image of Aunt Jemima in the American imagination. It is my wish to disrupt the contemporary viewer’s concept of the pancake box and invite a critical reading of the imagery because the package design originated from a legacy of slavery, but still sits on store shelves today

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo